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ABSTRACT
Succinate dehydrogenase (SDH)-deficient renal cancer is
a rare renal cancer subtype recently accepted by the
World Health Organization as a unique subtype of renal
cell carcinoma (RCC). Here we report a case of 17-year-
old man. The detailed evaluation indicated occurrence
of the SDHB-deficient RCC. The genetic testing revealed
no germline mutation in SDH genes. Immunohistochem-
istry showed SDHB deficiency, overexpression of pyru-
vate kinase M2 and dramatic downregulation of
fructose-1,6-bisphosphatase metabolic enzymes, and
unaltered levels of phosphorylated AMP-activated
protein kinase and mammalian target of rapamycin.
Strong upregulation of INI1 and BRG1 and over-
expression of BAF180, subunits of SWI/SNF ATP-
dependent chromatin remodeling complex, were also
found. The identified tumor pathologically did not
resemble clear cell renal cell carcinoma (ccRCC), but
some metabolic alterations are common for both cancer
types. Thus, we postulate that the phenotypical differ-
ences between ccRCC and SDHB-deficient RCC may be
related to distinct molecular and metabolic alterations.
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Implications for Practice: Succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) is a rare renal tumor occur-
ring even in young patients. Until now, in all described and genetically tested cases, mutations and deletions in SDH genes
have been found. This article describes SDHB-deficient RCC without any germline mutations in SDH genes. Therefore,
genetic analysis for germline mutations in SDH genes in SDH-deficient RCC, especially in young individuals, should be
strongly recommended, although as of now it is not obligatory. This knowledge will allow improvement of patient monitor-
ing including both disease recurrence and new cancer appearance.
BACKGROUND
Succinate dehydrogenase (SDH)-deficient renal cell carci-
noma (RCC) was originally described in 2004. In 2016 it was
accepted by the World Health Organization as a separate
rare RCC subtype representing around 0.05%–0.2% of all
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RCCs [1]. Around 75% of all patients with SDH-deficient RCC
carry a germline mutation in the gene encoding the SDHB
subunit of the SDH complex, which is composed of four pro-
teins, SDHA, SDHB, SDHC, and SDHD. Mutations in the
SDHA, SDHC, and SDHD genes are less frequent. Until now
only 59 SDH-deficient RCC cases have been described [2–6].
Patients’ ages at diagnosis ranged from 14 to 76 years. Only
seven cases were reported for patients aged younger than
20 years [2]. Patients harboring SDH mutations have a life-
time risk to develop RCC of around 14% and are also pre-
disposed to develop paragangliomas, pheochromocytomas,
and gastrointestinal stromal tumors. Usually, SDH-deficient
RCC is diagnosed as a low-grade tumor with a good progno-
sis. The metastasis rate is approximately 33% [2].
SDH, the succinate dehydrogenase complex, is involved
in both the Krebs cycle (tricarboxylic acid cycle) and the
electron transport chain. SDH enables conversion of succi-
nate to fumarate [7]. SDH loss leads to overaccumulation of
metabolic intermediates, that is, succinate, a signaling mol-
ecule in processes involved in inflammation and cancer and
that affect chromatin status [8]. Some RCC types, such as
clear cell renal cell carcinoma (ccRCC), are characterized by
aberrations in the switch/sucrose non fermentable (SWI/
SNF) chromatin remodeling complex (CRC), which is
involved in the control of gene expression and cancer devel-
opment via chromatin structure [9].
CASE PRESENTATION
A 17-year-old man, otherwise healthy, reported pain on the
right side of his abdomen lasting a few weeks. No gastroin-
testinal stromal tumor, paraganglioma, or pheochromocy-
toma was reported in his family. On examination all
routinely tested parameters were normal. Ultrasonography
examination showed a pathological mass in the right
kidney.
Figure 1. SDHB-deficient renal cell carcinoma (RCC) in a 17-year-old man is characterized by metabolic aberrations related to glycol-
ysis and Krebs cycle. (A, B): Abdominopelvic computed tomography scan in transversal (A) and coronal (B) plan. The arrowheads
indicate the 35 mm renal mass in the right kidney. (C): Standard immunohistochemistry (IHC) summary. (D): Immunostaining for
SDHB. Staining for SDHB was positive in normal kidney tissue (upper panel) and negative in cancer cells (lower panel), indicative of
the SDHB deficiency in this type of cancer. Magnification, 20 (left panel) and 40 (right panel). (E): IHC for glycolysis enzyme
FBP1, which controls the proper glycolysis flux in the cell, indicates strong impairment of glycolysis in SDHB-deficient RCC. (F): IHC
for glycolysis enzyme PKM2 indicates strong accumulation of this enzyme in the cancer cells, suggesting strong metabolic alter-
ations in SDHB-deficient RCC. Magnification for FBP1 and PKM2, 40.
Abbreviations: FBP1, fructose-1,6-bisphosphatase; PKM2, pyruvate kinase M2; SDHA, succinate dehydrogenase A; SDHB, succinate
dehydrogenase B.
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Computed tomography (CT) of the abdomen and pelvis
(Fig. 1A) with contrast material confirmed the presence of
a solid mass (diameter 35 mm) at the back-lower pole of
the right kidney (Fig. 1B). CT scan of the chest revealed no
evidence for metastatic cancer. In April 2017 a partial right
nephrectomy was performed. The pathological examina-
tion revealed the occurrence of SDH-deficient RCC classi-
fied as International Society of Urological Pathology
nucleolar grade 2. The standard immunohistochemistry
(Fig. 1C) indicated negative SDHB staining in cancer cells
(Fig. 1D).
The genetic test for germline mutation in SDH was per-
formed; DNA was isolated from blood samples and exam-
ined using Ion Torrent next-generation sequencing (Thermo
Fisher Scientific, Waltham, MA). The sequencing for exon
panel of VHL, RET, SDHA, SDHB, SDHC, SDHD, SDHAF1,
SDHAF2, and MAX was successful with 100% coverage at
20 coverage depth. No germline mutations or deletions
were found. The exons not covered by the panel were addi-
tionally sequenced using the Sanger method.
Given the occurrence of metabolic alterations in
another RCC (ccRCC) [9], we examined the abundance of
fructose-1,6-bisphosphatase (FBP1) (Fig.1E) and pyruvate
kinase M2 (PKM2) (Fig. 1F) proteins in this case. We found
nearly complete loss of FBP1 and strong overexpression of
PKM2 in cancer cells compared with healthy tissue.
In ccRCC, mutations and aberrations of SWI/SNF CRC
occur [9, 10]. Thus, we examined the abundance of the
main SWI/SNF CRC subunits (INI1, BRM, BRG1, BAF155, and
BAF180; Fig. 2A–E). Whereas for BRM and BAF155 no alter-
ations were observed, BRG1 ATPase, INI1, and BAF180 were
overexpressed in SDHB-deficient cancer cells. Subsequently,
we tested the abundance of activated AMP-activated pro-
tein kinase (AMPK) (phosphorylated at Tyr172) and mam-
malian target of rapamycin (mTOR) kinase, as ccRCC
exhibits mTOR hyperactivation and loss of AMPK activity.
Figure 2. Overexpression of some subunits of SWI/SNF chromatin remodeling complex characterizes the succinate dehydrogenase
B (SDHB)-deficient renal cell carcinoma (RCC) case subjected to the partial nephrectomy. (A–E): Immunohistochemistry (IHC) for
main SWI/SNF subunits in normal kidney tissue and cancer, indicating overaccumulation of INI1 protein in SDHB-deficient RCC cells
(A), similar levels of BRM in healthy kidney tissue and SDHB-deficient RCC cells (B), overaccumulation of BRG1 in SDHB-deficient
RCC cells (C), similar levels of BAF155 in healthy kidney tissue and SDHB-deficient RCC cells (D), and overaccumulation of BAF180 in
SDHB-deficient RCC cells (E). (F, G): IHC staining indicated similar levels of p-AMPK (F) and mTOR (G) in normal and SDHB-deficient
cancer cells. (H): The antibody description and signal strength assessment used in normal kidney and tumor. (I): Abdominopelvic
computed tomography scan in transversal plan 1 year after surgery; arrowhead indicates the previous tumor site.
Abbreviations: CST, cell signaling technology; FBP1, fructose-1,6-bisphosphatase; mTOR, mammalian target of rapamycin; p-AMPK,
phosphorylated AMPK; PKM2, pyruvate kinase M2.
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No differences in AMPK activation (Fig. 2F) and mTOR abun-
dance (Fig. 2G) were found, further indicating that SDHB-
deficient RCC (Fig. 2H) and ccRCC are characterized by dif-
ferent metabolic alterations.
At follow-up with the patient 1 year after surgery, no
evidence of disease recurrence was found (Fig. 2I).
DISCUSSION
SDHB deficiency is usually caused by either point mutation
or deletion in the SDHB gene. Mutations in other SDH genes
may also result in SDHB deficiency.
Here we describe, for the first time, the SDHB-deficient
RCC without germline point mutations or deletions in any
SDH genes. Thus, the existence of SDH mutations seems not
to be an obligatory factor for occurrence of this cancer
type. This observation is consistent with higher frequency
of particular SDHB point mutations in the population than
the occurrence of SDHB-deficient cancers [11].
The studied case featured FBP1 loss and PKM2 over-
expression, suggesting the metabolic switch to aerobic gly-
colysis known as the Warburg effect [12]. Observed
metabolic disorders partially resembled these in ccRCC
(FBP1 loss, tricarboxylic acid impairment); however, SDHB-
deficient RCC accumulates succinate, whereas ccRCC accu-
mulates fatty acids.
In contrast to the loss of SWI/SNF CRCs observed in
ccRCC, here we found overexpression of BRG1, INI1, and
BAF180 subunits. Some SWI/SNF CRC subunits have been
reported as tumor suppressors; for example, transient INI1
restoration in ccRCC caused downregulation of metastasis-
related genes [9]. Other subunits may act as oncogenes; for
example, overexpression of BRM ATPase correlates with
increased expression of chemoresistance-related genes in
adenoid cystic carcinoma [12]. Thus, we postulate that the
differential aberrations in SWI/SNF CRC could be related to
different aggressiveness in ccRCC and SDHB-deficient RCCs.
Because of overexpression, the protective function of INI1
and BRG1 subunits may be more pronounced in the SDHB-
deficient RCC; however, it needs to be confirmed in a larger
group of patients. Additionally, in the SDHB-deficient tumor
neither overexpression of mTOR nor loss of AMPK activity
was found, confirming the different metabolic alterations in
ccRCC and SDHB-deficient RCC.
Conclusion
SDHB-deficient RCC primary tumor is characterized by met-
abolic aberrations, including FBP1 loss, PKM2 over-
expression, and overaccumulation of some SWI/SNF CRC
subunits. Loss of SDHB is not necessarily caused by muta-
tions in SDH genes.
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